** Jazz Pharmaceuticals' JAZZ.O shares rise 3% to $141.29
** Brokerage Morgan Stanley raises PT to $183 from $175, a 34.1% upside to the stock's last close; maintains "overweight" rating
** Says growth of Jazz's newer sleep disorder drug Xywav in H1 should offset ongoing switch from older drug Xyrem
** Sees 'meaningful expansion' opportunity for Jazz's breast cancer drug Ziihera
** Brokerage expects peak annual revenue of $240 million for brain tumor drug dordaviprone, Jazz's newly acquired drug from its buyout of Chimerix CMRX.O
** Six brokerages rate the stock "buy" or equivalent, one "neutral"; their median PT is $187.47, according to data compiled by LSEG
** JAZZ has risen 16.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。